AP2527A - Pyrazoline compounds as mineralocorticoid receptorantagonists - Google Patents
Pyrazoline compounds as mineralocorticoid receptorantagonistsInfo
- Publication number
- AP2527A AP2527A AP2009004822A AP2009004822A AP2527A AP 2527 A AP2527 A AP 2527A AP 2009004822 A AP2009004822 A AP 2009004822A AP 2009004822 A AP2009004822 A AP 2009004822A AP 2527 A AP2527 A AP 2527A
- Authority
- AP
- ARIPO
- Prior art keywords
- receptorantagonists
- mineralocorticoid
- pyrazoline compounds
- pyrazoline
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86360606P | 2006-10-31 | 2006-10-31 | |
| PCT/IB2007/003207 WO2008053300A1 (en) | 2006-10-31 | 2007-10-17 | Pyrazoline compounds as mineralocorticoid receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP2009004822A0 AP2009004822A0 (en) | 2009-04-30 |
| AP2527A true AP2527A (en) | 2012-12-06 |
Family
ID=39027523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2009004822A AP2527A (en) | 2006-10-31 | 2007-10-17 | Pyrazoline compounds as mineralocorticoid receptorantagonists |
Country Status (40)
| Country | Link |
|---|---|
| US (3) | US7781428B2 (es) |
| EP (1) | EP2089367B1 (es) |
| JP (1) | JP4977760B2 (es) |
| KR (1) | KR101107800B1 (es) |
| CN (1) | CN101541757A (es) |
| AP (1) | AP2527A (es) |
| AR (1) | AR063529A1 (es) |
| AT (1) | ATE537151T1 (es) |
| AU (1) | AU2007315884B2 (es) |
| BR (1) | BRPI0717937A2 (es) |
| CA (1) | CA2667966C (es) |
| CL (1) | CL2007003154A1 (es) |
| CO (1) | CO6160307A2 (es) |
| CR (1) | CR10725A (es) |
| CU (1) | CU23779B7 (es) |
| CY (1) | CY1112311T1 (es) |
| DK (1) | DK2089367T3 (es) |
| EA (1) | EA016370B1 (es) |
| ES (1) | ES2375877T3 (es) |
| GE (1) | GEP20115239B (es) |
| GT (1) | GT200700096A (es) |
| HN (1) | HN2007000437A (es) |
| HR (1) | HRP20120078T1 (es) |
| IL (1) | IL198241A0 (es) |
| MA (1) | MA30821B1 (es) |
| MX (1) | MX2009004662A (es) |
| MY (1) | MY145795A (es) |
| NI (1) | NI200900071A (es) |
| NO (1) | NO20091741L (es) |
| NZ (1) | NZ575923A (es) |
| PE (1) | PE20081472A1 (es) |
| PL (1) | PL2089367T3 (es) |
| PT (1) | PT2089367E (es) |
| RS (2) | RS20090208A (es) |
| SI (1) | SI2089367T1 (es) |
| TN (1) | TN2009000160A1 (es) |
| TW (1) | TWI357327B (es) |
| UA (1) | UA92670C2 (es) |
| UY (1) | UY30670A1 (es) |
| WO (1) | WO2008053300A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI431010B (zh) | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
| WO2011059784A1 (en) * | 2009-10-29 | 2011-05-19 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds |
| ES2566934T3 (es) | 2010-05-10 | 2016-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina |
| CA2798831A1 (en) | 2010-05-11 | 2011-11-17 | Pfizer Inc. | Morpholine compounds as mineralocorticoid receptor antagonists |
| JP6180930B2 (ja) | 2010-06-16 | 2017-08-16 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 創傷治癒過程における再上皮化を刺激するための方法及び組成物 |
| CN102372710A (zh) | 2010-08-18 | 2012-03-14 | 山东轩竹医药科技有限公司 | 作为盐皮质激素受体拮抗剂的并环类化合物 |
| WO2012048022A2 (en) * | 2010-10-05 | 2012-04-12 | Nova Southeastern University | Methods and compositions for therapeutic modulation of aldosterone levels in heart disease |
| AU2015282450C1 (en) | 2014-06-30 | 2018-09-20 | Astrazeneca Ab | Benzoxazinone amides as mineralocorticoid receptor modulators |
| WO2017064121A1 (en) | 2015-10-13 | 2017-04-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation |
| WO2018019843A1 (en) | 2016-07-26 | 2018-02-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis |
| US10633354B2 (en) | 2016-09-02 | 2020-04-28 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
| US11046646B2 (en) | 2017-08-09 | 2021-06-29 | Bristol-Myers Squibb Company | Alkylphenyl compounds |
| WO2019032631A1 (en) | 2017-08-09 | 2019-02-14 | Bristol-Myers Squibb Company | OXIME ETHER COMPOUNDS |
| CN109051490B (zh) | 2018-09-18 | 2024-07-23 | 深圳市鲸仓科技有限公司 | 可移动式密集存拣装置 |
| JP2023518168A (ja) | 2020-03-11 | 2023-04-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 対象が中心性漿液性脈絡網膜症を有するか、または有する危険性があるかどうかを決定する方法。 |
| EP4395785A1 (en) | 2021-08-31 | 2024-07-10 | Inserm (Institut National de la Santé et de la Recherche Scientifique) | Methods for the treatment of ocular rosacea |
| CN113679716B (zh) | 2021-10-13 | 2024-03-26 | 史大永 | 溴酚-吡唑啉化合物在治疗猫冠状病毒疾病中的应用 |
| CN114230457B (zh) * | 2022-01-04 | 2023-06-09 | 中山大学 | 一类2-亚苄基四氢萘酮衍生物及其制备方法和应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998009969A1 (en) * | 1996-09-05 | 1998-03-12 | Astra Pharmaceuticals Ltd. | Novel aryl-pyridazines |
| WO2005066161A1 (en) * | 2003-12-19 | 2005-07-21 | Eli Lilly And Company | Tricyclic steroid hormone nuclear receptor modulators |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1086068A (en) | 1964-09-02 | 1967-10-04 | Ici Ltd | Process for the whitening of polymeric materials and nitrogen-containing polycyclic compounds for use therein |
| BE789948A (fr) | 1971-10-13 | 1973-04-11 | Sandoz Sa | Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments |
| US3816438A (en) | 1972-12-22 | 1974-06-11 | Sandoz Ag | 2h(1)-benzothiepino(5,4-c)-pyrazoles and(1)-benzothiopyrano(4,3-c)-pyrazoles |
| US3843666A (en) | 1973-05-29 | 1974-10-22 | Sandoz Ag | Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles |
| US4866025A (en) | 1988-09-30 | 1989-09-12 | Eastman Kodak Company | Thermally-transferable fluorescent diphenylpyrazolines |
| DK0623122T3 (da) | 1992-01-23 | 1997-04-21 | Pfizer | Benzopyran og beslægtede LTB4-antagonister |
| GB9318691D0 (en) | 1993-09-09 | 1993-10-27 | Merck Sharp & Dohme | Therapeutic agents |
| ID16283A (id) | 1996-03-20 | 1997-09-18 | Astra Pharma Prod | Senyawa yang berguna dibidang farmasi |
| JPH10273467A (ja) | 1997-01-29 | 1998-10-13 | Snow Brand Milk Prod Co Ltd | 新規テトラロン又はベンゾピラノン誘導体及びその製造方法 |
| IT1292092B1 (it) | 1997-06-05 | 1999-01-25 | Geange Ltd | Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali |
| PT1073435E (pt) | 1998-04-30 | 2004-10-29 | Abbott Gmbh & Co Kg | Derivados triciclicos substituidos de pirazole com actividade de proteina-quinase |
| US6432974B1 (en) | 2000-02-04 | 2002-08-13 | Wyeth | Pyrrolo-isoquinoline and tetra-hydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-HT7 receptor |
| CA2478068C (en) | 2002-03-08 | 2011-02-08 | Merck & Co., Inc. | Dihydropyrazole compounds useful for treating or preventing cancer |
| AU2003230581A1 (en) | 2002-03-15 | 2003-09-29 | Eli Lilly And Company | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators |
| TW200400816A (en) | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
| CN101037438A (zh) | 2002-08-02 | 2007-09-19 | 沃泰克斯药物股份有限公司 | 用作gsk－3的抑制剂的吡唑组合物 |
| PL375979A1 (en) | 2002-09-18 | 2005-12-12 | Pfizer Products Inc. | Pyrazole derivatives as transforming growth factor (tgf) inhibitors |
| US20060235222A1 (en) | 2003-01-22 | 2006-10-19 | Eli Lilly And Company | Indole-derivative modulators of steroid hormone nuclear receptors |
| JP2007230869A (ja) | 2004-04-05 | 2007-09-13 | Takeda Chem Ind Ltd | アルドステロン受容体拮抗剤 |
| WO2006010142A2 (en) | 2004-07-14 | 2006-01-26 | Ligand Pharmaceuticals, Inc. | Mineralocorticoid receptor modulator compounds, processes for their preparation, and their use |
| WO2006012642A2 (en) | 2004-07-30 | 2006-02-02 | Exelixis, Inc. | Pyrrole derivatives as pharmaceutical agents |
| EP1844020B1 (en) | 2005-01-10 | 2017-09-06 | Exelixis, Inc. | Heterocyclic carboxamide compounds as steroid nuclear receptor ligands |
| EP1844768A1 (en) | 2005-01-19 | 2007-10-17 | Dainippon Sumitomo Pharma Co., Ltd. | Aromatic sulfone compound as aldosterone receptor modulator |
| AU2006212863A1 (en) | 2005-02-10 | 2006-08-17 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
-
2007
- 2007-10-17 GE GEAP200711240A patent/GEP20115239B/en unknown
- 2007-10-17 PL PL07825488T patent/PL2089367T3/pl unknown
- 2007-10-17 JP JP2009533977A patent/JP4977760B2/ja not_active Expired - Fee Related
- 2007-10-17 UA UAA200903302A patent/UA92670C2/ru unknown
- 2007-10-17 EA EA200970341A patent/EA016370B1/ru not_active IP Right Cessation
- 2007-10-17 MX MX2009004662A patent/MX2009004662A/es active IP Right Grant
- 2007-10-17 CA CA2667966A patent/CA2667966C/en not_active Expired - Fee Related
- 2007-10-17 BR BRPI0717937-5A2A patent/BRPI0717937A2/pt not_active IP Right Cessation
- 2007-10-17 AT AT07825488T patent/ATE537151T1/de active
- 2007-10-17 NZ NZ575923A patent/NZ575923A/en not_active IP Right Cessation
- 2007-10-17 CN CNA2007800433330A patent/CN101541757A/zh active Pending
- 2007-10-17 AU AU2007315884A patent/AU2007315884B2/en not_active Ceased
- 2007-10-17 PT PT07825488T patent/PT2089367E/pt unknown
- 2007-10-17 EP EP07825488A patent/EP2089367B1/en active Active
- 2007-10-17 RS RSP-2009/0208A patent/RS20090208A/sr unknown
- 2007-10-17 MY MYPI20091613A patent/MY145795A/en unknown
- 2007-10-17 WO PCT/IB2007/003207 patent/WO2008053300A1/en active Application Filing
- 2007-10-17 RS RS20120051A patent/RS52203B/en unknown
- 2007-10-17 SI SI200730830T patent/SI2089367T1/sl unknown
- 2007-10-17 DK DK07825488.5T patent/DK2089367T3/da active
- 2007-10-17 AP AP2009004822A patent/AP2527A/xx active
- 2007-10-17 KR KR1020097008836A patent/KR101107800B1/ko not_active IP Right Cessation
- 2007-10-17 ES ES07825488T patent/ES2375877T3/es active Active
- 2007-10-24 US US11/923,248 patent/US7781428B2/en not_active Expired - Fee Related
- 2007-10-29 UY UY30670A patent/UY30670A1/es not_active Application Discontinuation
- 2007-10-29 AR ARP070104787A patent/AR063529A1/es not_active Application Discontinuation
- 2007-10-30 TW TW096140838A patent/TWI357327B/zh not_active IP Right Cessation
- 2007-10-30 GT GT200700096A patent/GT200700096A/es unknown
- 2007-10-30 PE PE2007001482A patent/PE20081472A1/es not_active Application Discontinuation
- 2007-10-31 HN HN2007000437A patent/HN2007000437A/es unknown
- 2007-10-31 CL CL200703154A patent/CL2007003154A1/es unknown
-
2009
- 2009-04-17 CR CR10725A patent/CR10725A/es not_active Application Discontinuation
- 2009-04-17 CU CU20090058A patent/CU23779B7/es not_active IP Right Cessation
- 2009-04-20 IL IL198241A patent/IL198241A0/en unknown
- 2009-04-21 CO CO09040130A patent/CO6160307A2/es unknown
- 2009-04-24 TN TNP2009000160A patent/TN2009000160A1/fr unknown
- 2009-04-29 NI NI200900071A patent/NI200900071A/es unknown
- 2009-04-30 MA MA31831A patent/MA30821B1/fr unknown
- 2009-05-04 NO NO20091741A patent/NO20091741L/no not_active Application Discontinuation
-
2010
- 2010-07-12 US US12/834,117 patent/US20100280016A1/en not_active Abandoned
-
2011
- 2011-10-20 US US13/277,270 patent/US20120035131A1/en not_active Abandoned
-
2012
- 2012-01-23 CY CY20121100076T patent/CY1112311T1/el unknown
- 2012-01-23 HR HR20120078T patent/HRP20120078T1/hr unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998009969A1 (en) * | 1996-09-05 | 1998-03-12 | Astra Pharmaceuticals Ltd. | Novel aryl-pyridazines |
| WO2005066161A1 (en) * | 2003-12-19 | 2005-07-21 | Eli Lilly And Company | Tricyclic steroid hormone nuclear receptor modulators |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS1900033I1 (hu) | Szubsztituált enaminokarbonil vegyületek | |
| AP2527A (en) | Pyrazoline compounds as mineralocorticoid receptorantagonists | |
| ZA201000255B (en) | Substituted bicyclolactam compounds | |
| EP2034838A4 (en) | NOVEL CONNECTIONS | |
| EP2032142A4 (en) | NOVEL CONNECTIONS | |
| EP1981596A4 (en) | NEW CONNECTIONS | |
| GB0603550D0 (en) | Novel compounds | |
| EP1981900A4 (en) | NEW COMPOUNDS | |
| GB0605462D0 (en) | Novel compounds | |
| GB0602900D0 (en) | Novel Compounds | |
| EP2031965A4 (en) | NEW COMPOUNDS | |
| ZA200901570B (en) | Substituted azolin-2-YL-amino compounds | |
| GB0607840D0 (en) | Novel compounds | |
| GB0600483D0 (en) | Novel compounds | |
| GB0607892D0 (en) | Novel compounds | |
| GB0607736D0 (en) | Novel compounds | |
| GB0607529D0 (en) | Novel compounds | |
| GB0601288D0 (en) | Novel compounds | |
| GB0602237D0 (en) | Novel compounds | |
| GB0602800D0 (en) | Novel Compounds | |
| GB0602047D0 (en) | Novel compounds | |
| GB0606763D0 (en) | Novel compounds | |
| GB0601294D0 (en) | Novel compounds | |
| GB0606549D0 (en) | Novel compounds | |
| GB0607896D0 (en) | Novel compounds |